Article Sidebar

PDF
Date Published: 15/02/2023
Abstract Views: 339
Views PDF: 143
DOI: https://doi.org/10.51298/vmj.v521i2.4037
Issue
Vol. 521 No. 2 (2022)
Section
Các bài báo
How to Cite
Phạm , H. M. T., Huỳnh, T. C., Ngô, H. T., Nguyễn, S. N. ., & Đinh, L. U. N. (2023). A STUDY ON CLINICAL, SUBCLINICAL CHARACTERISTICS AND SHORT-TERM RESULTS OF SHORT DUAL ANTIPLATELET THERAPY IN PATIENTS AT HIGH BLEEDING RISK UNDERGOING POLYMER-FREE DRUG-COATED CORONARY STENTS WITH CHRONIC CORONARY DISEASE. Vietnam Medical Journal, 521(2). https://doi.org/10.51298/vmj.v521i2.4037

A STUDY ON CLINICAL, SUBCLINICAL CHARACTERISTICS AND SHORT-TERM RESULTS OF SHORT DUAL ANTIPLATELET THERAPY IN PATIENTS AT HIGH BLEEDING RISK UNDERGOING POLYMER-FREE DRUG-COATED CORONARY STENTS WITH CHRONIC CORONARY DISEASE

Huỳnh Minh Trí Phạm 1,, Trung Cang Huỳnh2, Hoàng Toàn Ngô3, Sơn Nam Nguyễn1, Lê Uyên Nhi Đinh1
1 An Giang Central General Hospital
2 Kien Giang Provincial General Hospital
3 Can Tho University of Medicine - Pharmacy

Main Article Content

Abstract

Background: Percutaneous coronary intervention (PCI) by catheter is incresingly popular and confirms its absolute role on the treatment of chronic coronary artery disease. Polymer-free drug-coated coronary stents not only minimize the duration of DAPT but also have a high resistance to restenosis during intervention. Objectives: To evalate the short-term results of short DAPT and identify the associated factors in patients at high bleeding risk. Materials  and method: We performed the prospective and cross-sectional study on 78 patients at high bleeding risk with chronic coronary artery disease at An Giang Center General Hospital. Results: The mean of age of the study subjects was 67,8±12,01. Clinical symptoms after intervention (NYHA, CCS) were clearly improved. The rate of adverse events after the follow-up of DAPT in patients at high bleeding risk was 17,9%, of which 50% had major bleeding risk requiring hospitalization. Female gender, age ≥75, Hb<10g/dL, BMI ≥23 were associated with adverse events. Conclusion: In patients at high bleeding risk requiring a shortened duration of DAPT, BioFreedom polymer-free drug-coated stents are safe and effective in chronic coronary intervention.

Article Details

Keywords

Polymer-free drug-coated stent, coronary artery, percutaneous coronary intervention, short dapt, Biofreedom

References

1. Nguyễn Mạnh Quân và cộng sự (2019), “Đánh giá hiệu quả trong can thiệp động mạch vành của stent phủ thuốc không polymer”, Tạp chí Tim mạch học Việt Nam, Số 86, tr. 34-39.
2. Nguyễn Mạnh Quân (2021), Đánh giá kết quả can thiệp bằng stent phủ thuốc không Polymer – BioFreedom ở bệnh nhân động mạch vành, Luận án Tiến sĩ Y học, Trường Đại học Y Hà Nội.
3. Philippe Garot et al (2017), “2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drugs-Coated Stents”, Journal of the American College of Cardiology, 69(2), pp. 162-171.
4. Philip Urban et al (2015), “Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk”, The New England Journal of Medicine, pp. 1-10.
5. Roxana Mehran (2021), “3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation”, Cardiovascular Interventions, 14(17), pp. 1870-1883.
6. Grigoris Chatzantonis (2020), “Real-world analysis of a Biolimus A9 polymer-free drug-coated stent with very short dual antiplatelet therapy in patients at high bleeding risk”, Herz, pp. 1-8.
7. Ron Waksman et al (2017), “Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial”, Cardiovascular Revascularization Medicine, 18(7), pp. 475-481.
8. Juhani Knuuti, William Wijins, Antti Saraste et al (2020), “2019 ESC Guidelines for diagnostic and management of chronic coronary syndromes: The Task Force for diagnosis and management of chronic coronary syndromes of the European Society of Cardiology”, European Heart Journal, 41(3), pp. 407-477.
9. Roxana Mehran, Sunil V. Raoo, Deepak L. Bhatt et al (2011), “Standardized Bleeding Definitions for Cardiovascular Clinical Trials”, Circulation, 123, pp. 2736-2747.